Q1 2025 Exagen Inc Earnings Call Transcript
Key Points
- Exagen Inc (XGN) reported its ninth consecutive quarter of increasing trailing 12-month average selling price (ASP), demonstrating consistent revenue growth.
- The company successfully won its first Administrative Law Judge (ALJ) hearing, setting a positive precedent for future reimbursement appeals.
- Exagen Inc secured a positive medical policy with TRICARE, potentially increasing ASP and expanding market access.
- The launch of new biomarkers contributed to a 6% increase in testing volume over the previous quarter, indicating strong market adoption.
- The company improved its financial position with a new credit facility from Perceptive Advisors, providing flexibility for future growth initiatives.
- Gross margin slightly decreased to 58.9% from 59.6% in the previous year, with expectations for improvement later in the year.
- Operating expenses increased by 7.5% year-over-year, driven by R&D and SG&A expenses, impacting profitability.
- The net loss for the first quarter was $3.8 million, compared to $3.4 million in the same period last year.
- Adjusted EBITDA loss was $2.5 million, slightly deeper than expected, raising concerns about reaching profitability targets.
- The company faces challenges in fully educating physicians about new biomarkers, which may take the majority of the year to achieve.
Greetings and welcome to the Exagen Inc first-quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions)
As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Ryan Douglas, Investor Relations for Exagen Inc. Thank you. You may begin.
Good morning and thank you for joining us. Earlier today, Exagen Inc released financial results for the quarter ended March 31, 2025. John Aballi, our President and Chief Executive Officer, and Jeff Black, our Chief Financial Officer, will host this morning's call. The recording of today's call and the press release announcing the quarterly results can be found on the company's website at www.exagen.com.
As today's call includes forward-looking statements, we encourage you to review the statements contained in today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
